Related Experiment Videos

Multitarget antithrombotic drugs

Miloš Ilić1, Danijel Kikelj, Janez Ilaš

  • 1Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia.

Current Topics in Medicinal Chemistry
|November 2, 2011
PubMed

Insights

Dual-acting drugs targeting multiple pathways offer improved prophylaxis and treatment for thromboembolic disorders, addressing a major health challenge. These innovative therapies aim to overcome limitations of single-target treatments for thrombosis.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Thromboembolic disorders represent a leading cause of morbidity and mortality globally.
  • Effective prophylaxis and treatment of arterial and venous thrombosis remain significant therapeutic challenges.
  • Current therapies often target single pathways, presenting opportunities for multi-target approaches.

Purpose of the Study:

  • To review dual-acting compounds for thrombosis treatment.
  • To explore inhibitors targeting coagulation enzymes and platelet aggregation.
  • To highlight advantages of simultaneous multi-target intervention.

Main Methods:

  • Literature review of dual inhibitors.
  • Analysis of compounds acting on coagulation and platelet aggregation.
  • Focus on dual anti-coagulant and anti-aggregatory agents.

Main Results:

  • Dual inhibitors of coagulation enzymes show promise.
  • Dual anti-aggregatory compounds offer novel mechanisms.
  • Combined anticoagulant/anti-aggregatory agents present a strategic advantage.

Conclusions:

  • Simultaneous multi-target intervention in thrombosis is a promising therapeutic strategy.
  • Dual-acting drugs may offer enhanced efficacy over single-target agents.
  • Further research into these compounds is warranted for clinical application.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...